



## Appendix

---

# Private Sector Commitments To Universal Health Coverage

UHC2030 Private Sector Constituency 2023 Statement

This appendix includes a series of case studies illustrating wide-ranging contributions of the private sector in accelerating progress towards UHC. Not all of the private sector companies mentioned in this appendix are members of the UHC2030 Private Sector Constituency. Inclusion does not mean endorsement by UHC2030 nor any of its members.

## 3 Introduction

## 4 Case studies

### 4 **1. Incorporate UHC principles, including to leave no one behind, into our business**

4 GHIT Fund

5 Pfizer Accord for a Healthier World

6 reach52 Model

### 7 **2. Deliver innovations that respond to the needs of all people including underserved populations, and make these safe, affordable, accessible and sustainable**

7 Medtronic LABS Programs

8 Philips Maternal Health in Underserved Communities

9 MEDx eHealthCenter B.V. Ghana e-Education

10 DCCC VODAN

11 ATC CSR Foundation India and Apollo Telemedicine Networking Foundation Digital Dispensaries

12 Novartis Health Family Programs

13 Novo Nordisk Human Insulin Thermal Solution

### 14 **3. Help strengthen the health workforce, responding to local context, priorities, and needs**

14 Johnson & Johnson Center for Health Worker Innovation

15 GSK and AMREF Malaria and TB Program

16 Program R.O.S.E. (Removing Obstacles for Cervical Screening)

### 17 **4. Contribute to efforts to raise the finance available for UHC**

17 Roche Nigeria Cancer Health Fund

18 MSD Impact Investing

19 Access Accelerated

### 20 **5. Champion and engage in multi-stakeholder policy dialogues that advance UHC**

20 ATOM Coalition

21 City Cancer Challenge (C/Can)

# The private sector contributions towards UHC

The uneven achievement of Universal Health Coverage (UHC) in countries around the world impacts billions of people through delays in screening, diagnosis and treatment and irregular uptake of health interventions. The COVID-19 pandemic has also led to a reversal of recent gains made in global health outcomes through the diversion of resources towards emergency response and disruptions to essential prevention and health services. Although recovery is underway, economic headwinds are slowing progress in getting back on track to UHC.

Most countries have mixed (public and private) health systems, and in many developing countries more than half of first encounters with the health system by people with a new ailment are through the private sector. And in settings where the public sector is the main provider of services, the private sector is a critical partner in the supply of medical technologies (medicines, vaccines, diagnostics, devices, and equipment). While many stakeholders are involved in making UHC a reality, it is worth underscoring that the private sector is a key player in all settings. The Action Agenda from the UHC2030 movement calls for greater and governed multi-sectoral engagement that advances UHC, and the private sector stands together with the global health community to support countries in accelerating their efforts to achieve UHC.

The private sector is a key driver of innovation, provides high quality care, and is often able to offer greater efficiency and improved access via new delivery models. There is a lot of ingenuity and innovation in the private sector that can be scaled to manage ongoing health challenges as well as future health crises.

The private sector plays a critical role in developing innovative medical products, technologies, and clinical services, that can help improve healthcare, strengthen health systems, and increase efficiencies. Many companies invest heavily in R&D to create new solutions that can address unmet medical needs, promote improved health and wellbeing as well as social and economic development, reduce environmental impacts, and increase energy efficiency.

Public – private collaboration is a must to ensure the benefits of innovation in health reach people wherever they live. Beyond developing new solutions, companies in the health field also contribute techniques and insights to UHC through innovative approaches and partnerships with governments and other stakeholders to improve access to quality care.

The case studies featured in this Appendix reflect the wide-ranging contributions and the long-term engagement of the health-focused private sector, and how the capabilities and expertise of the different parts of the private sector are contributing towards UHC objectives in a number of ways.

For example, digital health technologies – digital health records, telehealth and artificial intelligence (AI) – have the potential to expand health coverage, strengthen health systems, reduce costs, improve the quality of care, and strengthen health systems.

For its part, the innovative pharmaceutical industry plays a unique role by driving the innovation for nearly all the medicines and vaccines in use today. The industry continues to discover, develop, and deliver new solutions for which there are no existing treatment or preventive measures yet, and expands access to quality products through innovative and sustainable approaches, including health financing mechanisms, pricing and payment models adapted to health systems and varying levels of wealth.

The medical technologies industry saves, supports, and improves lives by producing the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments and follow-ups.

Reducing financial risk to needed care is addressed through the health insurance sector which provides pre-payment and risk pooling mechanisms to cover medical expenses, helping to protect people from potentially catastrophic financial risks of illness.

The self-care industry, which includes consumer healthcare companies, helps prevent certain conditions and improve recovery times, empowering individuals to look after their own health efficiently and conveniently, in collaboration with health and social care professionals.

Finally, the private sector plays a significant role in health service provision in many countries, covering the full continuum of essential health services, from health promotion to prevention, treatment, rehabilitation and palliative care. This requires skilled health workers providing quality, people-centered care.

Sustained political leadership is required to create an enabling environment for the development, deployment and use of these vital health technologies and innovations. This includes recognizing and sustaining innovation, robust regulatory and legal system, strong measurement frameworks, and promoting high-standard ethical decision-making.

# 1 Incorporate UHC principles, including to leave no one behind, into our business

## GHIT Fund


Active since: 2013

**Companies:** Eisai • Astellas • Chugai Pharmaceutical • Daiichi Sankyo • Otsuka • Shionogi • Sumitomo Pharma • Takeda • Mitsubishi

**Initiative:** Global Health Innovative Technology (GHIT) Fund

 **Strategy:** Drug development and research • Health service delivery

 **Scope:** Global commitment

 **Target population:** Children and youth • Men • Women • People with low incomes

**Among supporting partners:**

- Global Alliance for TB Drug Development (TB Alliance)
- Drugs for Neglected Diseases initiative (DNDi)
- Bill and Melinda Gates Foundation
- United Nations Developmental Program (UNDP)

### Program overview

Japan's government and its drug industry — the third largest in the world — bring Japan's technology, innovation, and insights to the development of drugs, vaccines, and diagnostics for the developing world. As the world's first public-private partnership, the GHIT Fund was established by the Government of Japan, the Bill & Melinda Gates Foundation, and five Japanese leading pharmaceutical companies. By 2018, the partnership extended its membership to 11 partners.

The GHIT Fund provides grants for R&D projects to counteract common global threats to the health of citizens in Japan. Since its inception, the GHIT Fund has facilitated research and development for Neglected Tropical Diseases (NTDs), malaria, tuberculosis (TB), and antimicrobial resistance (AMR).

### Results and milestones

- The GHIT Fund has provided over USD 17.7 million in grants to global partnerships developing innovative drugs and vaccines against malaria, TB, and NTDs, including leishmaniasis and Chagas disease.
- The GHIT Fund's latest investments include funds towards a vaccine that could block the transmission of two species of malaria, a rapid-fire test that can reveal a malaria infection in minutes, and the development of a new TB diagnostic test for HIV-positive patients.


See [Global Health Progress](#) for the full program overview.


# Pfizer Accord for a Healthier World

Active since: 2022

**Company:** Pfizer

**Initiative:** An Accord for a Healthier World

 **Strategy:** Health system strengthening • Supply chain • Financing • Regulation and legislation • Price schemes • Health service delivery – Screening • Health service delivery – Diagnosis • Health service delivery – Treatment

 **Scope:** Africa (30 countries) • Americas (Haiti) • Eastern Mediterranean (Afghanistan, Somalia, Sudan, Syria, Yemen) • Europe (Kyrgyzstan, Tajikistan) • South East Asia (Bangladesh, Myanmar, Nepal, North Korea) • Western Pacific (Cambodia, Laos, Solomon Islands)

## Program overview

An Accord for a Healthier World is a first-of-its-kind initiative to enable sustained, equitable access to high-quality, safe, and effective medicines and vaccines with the potential to improve the health of 1.2 billion people living in 45 lower-income countries. Under the Accord, Pfizer has committed to offer the full portfolio for which the company holds global rights on a not-for-profit basis to these countries. By doing so, the Accord aims to provide prevention and treatment options for those impacted by deadly infectious diseases, as well as heart disease, certain cancers, rare and inflammatory diseases, and more.

Alongside governments and multi-sector leaders, the Accord will focus on co-creating solutions for faster, more efficient supply pathways for medicines and vaccines as well as strengthening the resources, capabilities, and platforms that can enable quick, yet sustainable access to them, including technical expertise, training, diagnostic capacity, innovative financing, and beyond.

## Results and milestones

- In 2022, Rwanda became the first country to receive deliveries of Pfizer patent-protected medicines and vaccines through the Accord, including nine products to help treat or prevent life-threatening infectious and inflammatory diseases, and certain cancers. Together, the Rwandan Ministry of Health and Pfizer are working to provide professional healthcare education and training to support Rwandan medical specialists.
- In November 2022, Pfizer deployed its first Global Health Team to Rwanda to help identify opportunities for long-term supply chain optimization.

See [Global Health Progress](#) for the full program overview.

# reach52 Model


**Active since:** 2016


---


**Company:** reach52

**Initiative:** reach52's model

---

 **Strategy:** Community awareness and linkage to care • Health system strengthening • Supply chain • Health service delivery – Treatment • Health service delivery – Prevention • Health service delivery – Screening

 **Scope:** Africa (2 countries) • Asia (5 countries)

 **Target population:** Rural populations

---

**Supporting partners:**

- Bayer Consumer Health
- Johnson & Johnson
- Unilever

## Program overview

reach52 designs and implements innovative community health solutions for rural populations, employing thousands of digitally-equipped Agents, large data sets and a growing network of retail merchant partners.

Through partnerships with established Growth Partners, reach52 recruits thousands of Agents (typically existing government Community Health Workers) at scale, providing upskilling, and equipping them with an offline-first mHealth platform. Through collection of baseline data, Agents deliver hyper-targeted resident engagements focusing on health promotion, community screenings, and referrals to care. Residents can also access low-cost health products/medicines aligning to campaigns through a network of partnered retail merchants, made available by reach52's private-sector partners.

reach52 generates revenue through the sale of engagement-based campaigns to global firms in the pharma, consumer health, and FMCG sectors. This end-to-end health access platform is designed to help partners understand, engage and supply to disconnected rural communities with ease. Additional revenue is also generated through the wholesale of products to merchant partners.

## Results and milestones


- We are now in 2500 communities across seven countries and have created jobs for 14,000 community health Agents, who have improved the lives of 1.4m residents.
- External evaluation of reach52's model found an SROI of 2.1, indicating for every USD 1 invested, we save beneficiaries USD 2.10 in health costs.

See [reach52.com](https://reach52.com) for more info.


## Medtronic LABS Programs

**Active since:** 2016

<b>Company:</b>	Medtronic LABS
<b>Initiative:</b>	Data-driven, community-based population health management (Multiple program across countries of operation)

 <b>Strategy:</b>	Community awareness and linkage to care • Health system strengthening • Health service delivery – Screening • Health service delivery – Diagnosis • Health service delivery – Treatment
---	---

 <b>Scope:</b>	Africa (5 countries) • South Asia (3 countries) • North America (1 country)
--	---

 <b>Target population:</b>	Our programs target low-income populations, typically rural or peri-urban populations with limited physical or economic access to healthcare
--	--

<b>Supporting partners:</b> (3 of 36)	<ul style="list-style-type: none"> <li>→ Africa CDC</li> <li>→ The Global Fund</li> <li>→ German Agency for International Cooperation (GIZ)</li> </ul>
--	--

### Program overview

Medtronic LABS is an independent non-profit with the mission to expand access to healthcare for underserved patients and communities around the world. We design and implement tech-powered healthcare delivery models using our Open-Source platform, “SPICE”, that strengthen and extend health systems into local communities, delivering sustainable outcomes for underserved patients worldwide. Our programs enable health systems to transform community-based care by screening, diagnosing, and managing populations and use data to link to facility-based care in a way that meaningfully drives clinical outcomes. Our clinical areas include hypertension, diabetes, mental health, malaria, tuberculosis, HIV, maternal health, and disabilities.

These low-cost models enable high quality care to be readily accessible to underserved populations at the community level. Our private sector and grant-funded investments support localized training of existing health system staff and enable sustainability by transitioning cost-effective program ownership to health systems and governments over time (in progress in Ghana, Tanzania, Kenya).

### Results and milestones

- Our programs have screened 332,800 people to date.
- Of the 181,803 patients enrolled in our programs, 85,424 have already had clinically meaningful improvements in their conditions.

See [medtroniclabs.org](https://medtroniclabs.org) for more info.




# Philips Maternal Health in Underserved Communities

**Active since:** 2018

---

**Company:** Philips  
**Initiative:** Maternal health in underserved communities

---

 **Strategy:** Health system strengthening  
 **Scope:** Americas (Brazil) • Africa (Kenya, Republic of Congo) • South East Asia (Indonesia, India)  
 **Target population:** Women

---

**Supporting partners:**  
→ UNFPA  
→ Bill and Melinda Gates Foundation (BMGF)

## Program overview

Philips has targeted efforts underway to improve maternal health in underserved communities. We share personalized, preventive, and proactive health information to expectant mothers via our Pregnancy+ app and deliver obstetric ultrasound technology and workflow solutions to healthcare practitioners.

In Brazil, Philips has partnered with UNFPA to deploy the Pregnancy+ app to pregnant women to feel better informed, prepared, and confident. In Kenya, Philips and Philips Foundation are exploring scalable, evidence-based models to improve access to obstetric ultrasound services in underserved communities. In Indonesia, Philips partnered to help healthcare practitioners to better manage high-risk pregnancies and track mother and child health post-delivery using ultrasound.

Philips R&D is developing an artificial intelligence (AI) based application suite to improve the quality and accessibility of obstetric care in LMIC. Such application suite will be deployed on Philips Handheld Ultrasound Lumify. This R&D project is supported through funding from the Bill and Melinda Gates Foundation.

## Results and milestones

- The most downloaded pregnancy app in the world Pregnancy+ is being made available and localized for expectant mothers in underserved communities; the app was downloaded by 800,000 users in underserved communities to-date.
- By innovating in business models, financing, and technology to improve access to handheld ultrasound services, we improved 1.7M lives in 2022 in underserved communities, incl. expectant mothers as part of them.

See [website](#) for more info.



# MEDx eHealthCenter B.V. Ghana e-Education

Active since: 2022

**Company:** MEDx eHealthCenter B.V.

**Initiative:** Ghana e-Education

 **Strategy:** Material Care/P2P Education

 **Scope:** Africa (Ghana)

 **Target population:** 110,000 nurses

**Supporting partners:** → N&MC

→ RVO

## Program overview

Lockdowns in response to COVID-19 have disrupted regular classes in practically every country globally, including Ghana, negatively impacting the teaching and learning processes for Ghanaian nurses and midwives. To ensure continuous learning, many countries adopted e-education systems and implemented digital tools and applications. E-education offers advantages such as mass continuous learning, free access to information, expanded opportunities for quality education, and new directions for people regardless of social status, nationality, and physical capabilities. The nursing/midwifery education process continues to face obstacles, and the COVID-19 pandemic has forced traditional work-life and school-life practices into an irreversible transition. To address these issues, stakeholders need to move beyond traditional education methods and stereotypes and adopt an e-education paradigm for nursing/midwifery education delivery and capacity building. Collaborative training opportunities should also be provided to benefit patients and Ghana as a whole.

## Results and milestones

- Current state of Nurses Education and training have been investigated and documented: 75.08% of respondents had daily internet access and 82.46% owned an internet-enabled device, with 73.23% using mobile phones for e-learning. 63.08% preferred specialist nursing/midwifery courses. 64.31% wanted both online and offline access to an e-education platform.
- Execution of the MEDx Digital Hospital Material care Module is currently being adapted to be deployed among pilot groups: Ongoing.

See [website](#) for more info.




# DCCC VODAN

**Active since:** 2020

---

<b>Organization:</b>	Digital Connected Care Coalition
<b>Initiative:</b>	VODAN – Africa: realizing the potential of health data in African countries

---

 <b>Strategy:</b>	Health system strengthening • Development and research • Public health
 <b>Scope:</b>	Africa (9 countries and growing)
 <b>Target population:</b>	From facilitating health services improvement at individual level, to regional disease monitoring

---

<b>Supporting partners:</b>	→ Africa University Network
(3 of 20)	→ GO-FAIR
	→ DCCC members

## Program overview

VODAN-Africa aims to realize the full potential of health data for African countries. It is set up as the independent, trustworthy, and safe and secure by design, federated health data infrastructure. Such infrastructure is a boundary condition for resilient health systems and provides a basis for research, monitoring and innovation in health. VODAN can facilitate early warning of disease outbreaks, medication development, the development of health insurance, and assist in developing digital health solutions.

VODAN includes health facilities in difficult to reach and unconnected areas, thus expanding access to care and early warning for epidemics to these facilities, and reducing urban bias.

North Star is the creation of a financially self-supporting, federated African Health Data Space where (1) data always remains under control of the health facilities; and (2) can contribute to quality health services at the point of care, while (3) also, deidentified, help understand health dynamics in Africa.

## Results and milestones

- Initially tested in three countries as an early warning and monitoring system for viral outbreaks, VODAN has already (March 2023) been deployed in 88 health facilities across 9 African countries.
- Creation and deployment of data stewardship network across 9 countries to ensure quality of data and data-exchange.


See [website](#) for more info.


# ATC CSR Foundation India and Apollo Telemedicine Networking Foundation Digital Dispensaries


**Active since:** 2022

**Companies:** ATC CSR Foundation India and Apollo Telemedicine Networking Foundation under the aegis of World Economic Forum's (WEFs) [Edison Alliance](#)

**Initiative:** Digital Dispensaries in Madhya Pradesh

 **Strategy:** Community awareness and linkage to care • Health system strengthening • Development and research • Health service delivery – Treatment • Health service delivery – Prevention • Health service delivery – Screening • Health service delivery – Diagnosis

 **Scope:** To setup and operate paramedic-driven digital dispensaries by way of teleconsultations to help the disadvantaged, rural communities in Central India and enable access to digital healthcare, free of cost. The services provided, by way of sustainable donor funding, are: Primary Teleconsultations • Specialty & super specialty teleconsultations • Laboratory services • Pharmacy • Social health education sessions • Non-communicable diseases screening

 **Target population:** The facilities are accessible to around 200 villages across four districts in Madhya Pradesh which cover around 250,000 people including: Below-poverty-line (BPL) families • Specific focus on women and elderly population • Pediatric care for children • Marginalized people

**Supporting partners:**

- ATC (American Tower Corporation) CSR Foundation, India – donor and connectivity partner
- Apollo Telemedicine Networking Foundation – Implementation, Clinical service delivery, and operations.

## Program overview

ATC CSR Foundation India, the CSR arm of American Tower Corporation (ATC) India, as a part of its Digital Communities program, together with the Apollo Telemedicine Networking Foundation, launched five digital dispensaries in rural Madhya Pradesh in March 2022. These digital dispensaries are operational at Indorama, Depalpur, Barwaha, Icchawar, and Rehti. They are accessible to around 200 villages across 4 districts, offering healthcare services to nearly 250,000 people. The digital dispensaries conduct free screenings and doctor consults virtually, on a daily basis. They also stock and dispense 60+ essential drugs to patients.

## Results and milestones

- Between March 2022 and February 2023, the digital dispensaries have provided 9,886 General physician teleconsultations, 1,236 specialist consultations, and diagnostic services to more than 5,700 beneficiaries.
- Topline value to operate five digital dispensaries per year is approximately USD 164,000.
- As this is a capital-intensive project, multi-stakeholder collaboration and additional donors are crucial to its success.
- Until February 2023, 63.7% of teleconsultations availed were by women vis-à-vis 36.3% by men.
- Since its launch, based on services rendered in the program including teleconsultations, diagnostic and pharmacy services, and social awareness programs, the initiative has been able to bring the cost of service to less than USD 6 on average.

See [atcdd.ind.in](http://atcdd.ind.in) for more info.

# Novartis Health Family Programs


**Active since:** 2007


---


**Company:** Novartis

**Initiative:** Novartis Healthy Family Programs

---

 **Strategy:** Community awareness and linkage to care • Health system strengthening • Health service delivery

 **Scope:** Africa (Kenya) • South East Asia (India) • Western Pacific (Vietnam)

 **Target population:** Children • Women • People with low incomes • Marginalized/indigenous people • Rural populations

---

**Among supporting partners:**

- Local NGOs
- Global NGOs
- Ministries of Health

## Program overview

The Novartis Healthy Family model is based on six “A’s”: Awareness, Affordability, Adherence, Adaptability, Availability, and Alliances. Novartis recruits and trains locals in remote villages to become “health educators.” They help inform communities about health, disease prevention, and the benefits of seeking timely treatment. Local teams also work with doctors to organize health camps in remote villages – mobile clinics that provide access to screening, diagnosis, and therapies. “Health supervisors” serve as the initiative’s local sales force, interacting with local pharmacies and doctors.

The initiative also offers affordable medications for communicable and non-communicable diseases. These are adapted to local market conditions, and to the diseases most prevalent in the rural areas of each country. To be included in the portfolio, products need to be simple to use and relevant to local patients. The current portfolio includes antibiotics, non-steroidal anti-inflammatory agents, diabetes, hypertension, and dyslipidemia medicines, as well as anti-infectives that can be used in gynecological treatments.

## Results and milestones

- The first program (“Arogya Parivar”) was launched in 2007 in India and became self-sustaining in less than three years. The program is currently being refreshed to refine the therapeutic area focus in line with decentralization of specialty disease care.
- Given Arogya Parivar’s success in India, Novartis has rolled out similar programs in Vietnam and Kenya. Novartis plans to evolve the portfolio to include more innovative medicines.

See [Global Health Progress](#) for the full program overview.

# Novo Nordisk Human Insulin Thermal Solution


**Active since:** 2020


---


**Company:** Novo Nordisk

**Initiative:** Human insulin thermal solution

---

 **Strategy:** Supply chain

 **Scope:** Relevant low- and middle-income countries worldwide

 **Target population:** People with diabetes affected by humanitarian crises and hard-to-reach populations, particularly in hot climates

---

**Supporting partners:** Label update was carried out by Novo Nordisk, subsequently submitted the products for the WHO prequalification process and prequalification obtained in September 2022.

## Program overview

Novo Nordisk has a cross-functional collaboration team that focuses on evaluating more flexible insulin storage. The storage instructions for insulin vary, but for most, the recommendation from the moment of manufacture up until the product is in-use is to keep the insulin cool – at refrigerator temperatures around 2°C – 8°C range. In many low- and middle-income countries (LMICs) and humanitarian settings, temperatures often exceed this range, and refrigeration may not always be available or reliable.

Novo Nordisk sought to address this barrier by challenging and re-evaluating the thermal stability of its short-acting and intermediate-acting human insulin products. Both are widely used in LMICs and humanitarian settings where revised storage guidance could reduce the burden of diabetes management and improve the lives of people with diabetes using the products.

In April 2022, Novo Nordisk received a positive scientific opinion from the European Medicines Agency (EMA), and Novo Nordisk is now seeking national approvals of more flexible storage conditions in relevant low- and middle-income countries.

## Results and milestones

→ By end-March 2023 the label update has been approved in ten countries.

See [website](#) for more info.

# Johnson & Johnson Center for Health Worker Innovation

Active since: 2019

**Company:**

Johnson & Johnson

**Initiative:**

Johnson & Johnson Center for Health Worker Innovation



**Strategy:**

Community awareness and linkage to care • Health system strengthening



**Scope:**

Global commitment



**Target population:**

Children • Women • People with low incomes • Marginalized/indigenous people • Rural populations

**Among supporting partners:**

- The Global Fund
- UNICEF
- International Council of Nurses

## Program overview

The Center was founded to take on two of the toughest barriers to achieving UHC and the [SDGs](#) — closing a [10 million health worker shortage](#) and equipping health workers to thrive. The Center leverages a people-first model, focusing on equipping health workers across the globe with the skills, resources, and support they need to improve quality of care and strengthen community-based health systems.

Championing global health equity is key to the Center's mission and a core priority of Johnson & Johnson's [ESG strategy](#). Frontline health workers are often the first and only link between communities and health systems. With [half the world](#) lacking access to basic, essential health services, supporting health workers and rebuilding primary healthcare, which has been underfunded for decades, will be critical to achieving global health priorities.

## Results and milestones

- As of October 2022, the Center's programming reached over 755,000 frontline health workers, primarily nurses, and community health workers in 2021 alone — already 74% of its 10-year 2030 target. This is primarily a result of the reach of J&J's [digital health programming](#).
- J&J is working to recalibrate its targets for the years ahead in line with its mission to achieve health equity and access to health for everyone, everywhere.

See [Global Health Progress](#) for the full program overview.

# GSK and AMREF Malaria and TB Program


Active since: 2021

---

**Company:** GSK

**Initiative:** Malaria and TB program in Ethiopia and Kenya

---

 **Strategy:** Health system strengthening • Health service delivery – treatment • Health service delivery – diagnosis

 **Scope:** Africa (2 countries)

---

**Supporting partners:**

- Global Fund (in Kenya)
- USAID (in Ethiopia)

## Program overview

The overall goal was to improve the prevention, detection, diagnosis and management and TB and malaria in Kenya and Ethiopia by sustainably strengthening health systems in both countries. It is the latest iteration of Amref Health Africa and GSK's longstanding partnership to address malaria and TB in these high-burden countries. In both countries, the program's objectives were to train frontline health workers for effective diagnosis/treatment of malaria and TB, with a focus on mothers and children in Ethiopia. In Kenya, the aims were also to train healthcare managers in leadership, management and governance, strengthen community health systems and strengthen TB and malaria surveillance and data use for decision making. In Ethiopia, the aims were to gain External Quality Assurance (EQA) on lab services, strengthen PHC through knowledge management to integrated programming and improve community level contribution for TB and malaria case detection.

## Results and milestones

- 5,877 frontline health workers trained and supported 370 health facilities and 435 community health units/posts. We supported supervision, mentorships and dissemination of guidelines and data tools
- In Kenya, we supported the development of Homa Bay County HRH Strategic Plan and Kakamega CHS Policy. 1,884 patients screened in Ethiopia for TB through a mobile screening outreach initiative.

See [website](#) for more info.

# Program R.O.S.E. (Removing Obstacles for Cervical Screening)

**Active since:** 2019

---

**Company:** Roche Diagnostics

**Initiative:** Program R.O.S.E (Removing Obstacles to Cervical Screening)

---

 **Strategy:** Health system strengthening • Health service delivery – Diagnosis

 **Scope:** Cervical Cancer Screening

 **Target population:** Women

---

**Supporting partners:**

- University of Malaya
- Australian Centre for the Prevention of Cervical Cancer (formerly known as VCS, Victorian Cytology Service Inc.)
- Roche Diagnostics

## Program overview

Cervical cancer is the third major cancer among women in Malaysia. Many barriers to screening, such as lack of information, time constraint, financial cost, and fear of treatment has resulted in the low coverage screening rates in the South East Asian country.

Program R.O.S.E. (Removing Obstacles to Cervical Screening) is a cervical health initiative led by the University of Malaya in collaboration with Australia's VCS Foundation and Roche Diagnostics, among other partners. It integrates self-sampling, HPV testing and a digital screening platform to improve the patient journey for women in Malaysia. In its pilot phase, Roche Diagnostics primarily funded the centralized HPV DNA testing used through a study to assess the feasibility and acceptability of a centralized cervical screening strategy utilizing self-collected samples. The study found the strategy most suitable for implementation.

## Results and milestones

- Twenty-one thousand nine hundred fifty-seven women have been screened since program inception, and over 70 potential cervical cancer cases have been identified and linked for treatment.
- The program has expanded to over 150 community locations across twelve states in Malaysia.




See [programrose.org](http://programrose.org) for more info.



## Roche Nigeria Cancer Health Fund

**Active since:** 2020

<b>Company:</b>	Roche Pharmaceuticals
<b>Initiative:</b>	Nigerian Cancer Health Fund

 <b>Strategy:</b>	Financing • Health service delivery – Treatment
 <b>Scope:</b>	Africa (Nigeria)
 <b>Target population:</b>	People with low incomes

<b>Supporting partners:</b>	<ul style="list-style-type: none"> <li>→ International Finance Corporation (IFC)</li> <li>→ Healthcare Federation of Nigeria</li> <li>→ Nigeria National Health Insurance Scheme</li> </ul>
-----------------------------	---

### Program overview

Health insurance in Nigeria is not widespread and does not offer comprehensive cancer care coverage. Many cancer patients have to go without necessary treatments or begin their medical treatment but stop because they cannot afford the out-of-pocket costs associated with their cancer care.

In 2020, Roche led a private-sector coalition which, with the support of the International Finance Corporation (IFC) and Nigerian public authorities, led to the creation of the Nigerian Cancer Health Fund (CHF). The CHF's goal is to enable standard of care cancer treatment to underprivileged populations regardless of their ability to pay, and to strengthen the national cancer care ecosystem by improving quality of services. The CHF provides access to funding of up to USD 4,865 for treatments, chemotherapy, and radiation therapy services for people with breast, cervical, and prostate cancers. It is being piloted in designated centers across the country.

### Results and milestones

- Since 2020, approximately USD 4 million has been allocated, offering the potential to provide comprehensive care for people with breast, prostate, and cervical cancers.
- There are six public health institutions involved in the pilot phase, one in each geopolitical zone of the country.

See [Global Health Progress](#) for the full program overview.




# MSD Impact Investing

Active since: 2015

---

**Company:** MSD  
**Initiative:** Impact Investing

---

 **Strategy:** Health service delivery  
 **Scope:** Americas (2 countries) • Africa (several countries) • Asia (several countries)  
 **Target population:** Low- and middle income

---

**Supporting partners:**

- HealthQuad
- Mamotest
- Evercare

## Program overview

Impact investing is one of our core approaches to advancing sustainable global health systems. Through impact investing, we deploy financial resources in ways that may generate not only improved access to health care for underserved populations, but also financial returns and commercial opportunities – all while growing a sustainable global health ecosystem and attracting additional capital and partners. In our impact investing portfolio we seek to address complementary facets of a sustainable and resilient global health ecosystem, e.g., physical infrastructure, financial inclusion, digital and diagnostic solutions, and emergency response.

In addition to our portfolio of eight fund investments and two direct investments, we also advocate and engage in policy dialogue at the global, regional, and national level to promote improved and sustainable investment in health. We support efforts to identify challenges to healthcare financing, engage policy and financing experts across sectors, and promote a continuum of evidence-based approaches by which countries can strengthen investment in healthcare.

## Results and milestones

- 32 million people reached since 2018
- USD 51M in investment commitments

See [website](#) for more info.

# Access Accelerated

**Active since:** 2017

## Companies:

Bayer AG • Bristol Myers Squibb • Chugai Pharmaceutical • Daiichi Sankyo • Eisai • Eli Lilly and Company • Ipsen • Menarini Group • Sumitomo Pharma • Takeda • UCB • IFPMA • Astellas

## Initiative:

Access Accelerated Initiative



## Strategy:

Health service delivery • Community awareness and linkage to care • Health system strengthening • Supply chain • Financing • Regulation and legislation



## Scope:

Global commitment

## Among supporting partners:

- World Bank
- RTI International
- Boston University

### Program overview

Access Accelerated is a unique cross-industry collaboration that reduces barriers to sustainable and scalable solutions to NCD prevention, treatment, and care in LMICs. They bring global reach and local expertise in partnership with countries, civil society, multilaterals, and NGOs to support cross-sectoral dialogue and drive health systems strengthening in alignment with UHC objectives and priorities.

The World Bank Group and Access Accelerated have been working to advance joint action in-country across three areas:

- Generating high-level evidence on the economic impact of NCDs to make the case for national health policies that can be integrated into countries' national UHC agendas
- Accelerating public and private investment in NCD prevention, treatment, and care through a portfolio of projects that inform national scale-up and support innovative financing for NCDs
- Optimizing public-private partnership engagement for impact, tracking progress against a results-based monitoring and evaluation system that facilitates evidence-based decision making to guide future NCD programming.

### Results and milestones

- The partnership has supported the World Bank on 40+ projects across 36 LMICs by catalyzing new public investment in NCDs and informing USD 2.1 billion in health system investments.
- From 2017 to 2022, Access Accelerated also partnered with NGOs, City Cancer Challenge, NCD Alliance, PATH, and the World Heart Federation to support countries to improve access to NCD care.

See [Global Health Progress](#) for the full program overview.

# ATOM Coalition

**Active since:** 2022

**Companies:** AstraZeneca • Bristol Myers Squibb • Gilead • Novartis • Roche • Sanofi • Teva Pharmaceutical • Amgen • Eli Lilly and Company • MSD • Pfizer • IFPMA

**Initiative:** Access to Oncology Medicines (ATOM) Coalition

 **Strategy:** Community awareness and linkage to care • Health system strengthening • Supply chain • Financing • Regulation and legislation • Drug development and research • Licensing agreements • Health service delivery – Treatment • Health service delivery – Diagnosis

 **Scope:** Global commitment

- Among supporting partners:**
- The Union for International Cancer Control (UICC)
  - Medicines Patent Pool (MPP)
  - Access to Medicine Foundation
  - PATH
  - Project Echo
  - ASCO

## Program overview

The ATOM Coalition was launched on the sidelines of the 75th World Health Assembly (WHA75) by UICC and its partners. It brings together more than 30 expert organizations from civil society, the public sector, and private sector in the shared ambition to reduce suffering and deaths caused by cancer in LLMICs. It will do this by increasing access to quality-assured essential cancer medicines and the capacity to use these medicines appropriately.

In the first phase of operations (4-5 years), the ATOM Coalition will support the implementation of intensive coordinated capacity building activities in five to 10 countries, expanding to other LLMICs over time. It will also focus on increasing access to medicines in 46 countries classified as LLMICs. Priority will be placed on medicines on the WHO Essential Medicines List (EML) or those likely to be included in the future that treat cancers with the highest incidence-to-mortality rate in LLMICs.

## Results and milestones

- The ATOM Coalition Medicines Expert Advisory Group has put forward a priority list of 17 generic and biosimilar medicines for cancer.
- Under ATOM, Novartis granted the MPP a non-exclusive licence for nilotinib — a treatment for chronic myeloid leukemia on the WHO EML — becoming the first company to sign a non-exclusive voluntary license for an oncology medicine.


See [Global Health Progress](#) for the full program overview.

# City Cancer Challenge (C/Can)

**Active since:** 2017

**Companies:** AstraZeneca • Access Accelerated • Amgen • Astellas • Boehringer Ingelheim • Bristol Myers Squibb • Chugai • MSD • Novartis • Pfizer • Roche • Sanofi • Takeda • IFPMA

**Initiative:** City Cancer Challenge (C/Can)

 **Strategy:** Community awareness and linkage to care • Health System Strengthening • Health service delivery – Treatment • Health service delivery – Prevention • Health service delivery – Screening • Health service delivery – Diagnosis

 **Scope:** Global commitment

**Among supporting partners:**

- International Finance Corporation (IFC) – World Bank
- Clinton Health Access Initiative
- United Nations Institute for Training and Research (UNITAR)
- World Health Organization (WHO)

## Program overview

C/Can supports cities achieve better cancer care by implementing changes that can be scaled up and replicated across health services. The initiative is based on the premise that cities provide a unique ecosystem to test and drive innovation in cancer care — meeting people’s needs from the ground up.

The C/Can model invests in enhancing connections between people, policies, and processes to build capacity and resilience. It convenes policy makers, healthcare providers, patient groups, and partners, creating communities to support the journey to self-reliance. Cities apply to join C/Can and are considered based on their commitment to fighting cancer, alongside other criteria. Once a city is accepted, they will work with C/Can to identify and engage stakeholders, assess their needs, develop solutions, and execute and sustain projects to improve cancer.

## Results and milestones

- There are 13 cities working with C/Can on five areas of action: improving health information systems, developing health workforce capacity, catalyzing health financing, strengthening leadership and governance, and strengthening health service delivery.
- A new call for city applications will be launched in 2023.

See [Global Health Progress](#) for the full program overview.

## About UHC2030 Private Sector Constituency

UHC2030 is the movement to accelerate progress towards UHC by providing a multi-stakeholder platform that promotes collaboration on health systems strengthening at the global and country levels. The **UHC2030 Private Sector Constituency**, hosted by the World Bank, convenes private sector actors and **fosters dialogue and collaboration** across the private sector and with other UHC2030 partners, constituencies and networks. Members are for-profit entities within the health value chain such as service providers, health insurers, and manufacturers and distributors of medicines, diagnostics, health products and innovative technologies.



[UHC2030.org](https://UHC2030.org)



[@UHC2030](https://twitter.com/UHC2030)